Takeda Pharmaceutical Co Ltd R&D and Plasma-Derived Therapies Day - Tokyo Transcript
[Interpreted] Good morning, ladies and gentlemen. Thank you for joining us today out of your busy schedule. My name is Ayako Iwamuro. I'm from Investor Relations of Global Finance. Very nice to meet you all.
We will have PDT day during the morning. And I'd like to introduce to you the speakers of the PDT day part. We also have a live streaming of today's meetings. So I'd like to introduce to you the speakers of today's morning. First, Julie Kim, President of Plasma-Derived Therapies Business Unit; and Christopher Morabito, Head of R&D Plasma-Derived Therapies.
So now we would like to begin the meeting. But just as a reminder, in today's PDT Day and R&D Day, we will be discussing forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those discussed today. The factors that could cause our actual results to differ materially are discussed in our most recent Form 20-F and in our other SEC filings.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
